Xtl Biopharmaceuticals (XTLB) EPS (Basic) (2009 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly EPS (Basic) of -$0.04 for Q4 2024, down 278.02% year-on-year from $0.02 in Q1 2024, and down 345.37% on a QoQ basis from $0.02 in Q3 2024.
Xtl Biopharmaceuticals (XTLB) EPS (Basic) (2009 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported EPS (Basic) for 16 consecutive years, with -$0.04 the latest figure, recorded in Q4 2024.
- Quarterly EPS (Basic) fell 278.02% year-over-year to -$0.04 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was -$0.0 (up 82.16% YoY) and the FY2025 annual result came in at -$0.01, up 81.22% from the prior year.
- EPS (Basic) eased to -$0.04 in Q4 2024 per XTLB's latest filing, from $0.02 in the prior quarter.
- Over the last five years, EPS (Basic) for XTLB reached as high as $0.02 in Q3 2024 and fell as low as -$0.04 in Q4 2024.
- A 5-year average of -$0.0 and a median of -$0.0 in 2022 frame the typical range for EPS (Basic).
- The largest YoY upside for EPS (Basic) was 112039136.0% in 2021 against a maximum downside of 16854715.31% in 2021.
- Year by year, EPS (Basic) stood at -$0.0 in 2020, then plunged by 10873850.49% to -$0.0 in 2021, then tumbled by 566.05% to -$0.01 in 2022, then gained by 13.36% to -$0.01 in 2023, then slumped by 278.02% to -$0.04 in 2024.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.04, $0.02, and -$0.01 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.16 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 0.00 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 0.00 |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 7.59 |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -2.29 |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -0.04 |
| Sep 30, 2024 | 0.02 |
| Jun 30, 2024 | -0.01 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | -0.01 |
| Sep 30, 2023 | 0.01 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | -0.01 |
| Dec 31, 2022 | -0.01 |
| Sep 30, 2022 | 0.00 |
| Jun 30, 2022 | 0.00 |
| Mar 31, 2022 | 0.00 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | -0.01 |
| Jun 30, 2021 | 0.01 |
| Mar 31, 2021 | 0.00 |
| Dec 31, 2020 | 0.00 |
| Sep 30, 2020 | 0.00 |
| Jun 30, 2020 | 0.00 |
| Dec 31, 2019 | -0.01 |